Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia

Archives of General Psychiatry

Volumn 61, Issue 10, 2004, Pages 1005-1013

  Davidson, Jonathan R T ^a,c   Foa, Edna B ^b   Huppert, Jonathan D ^b   Keefe, Francis J ^a   Franklin, Martin E ^b   Compton, Jill S ^a   Zhao, Ning ^b   Connor, Kathryn M ^a   Lynch, Thomas R ^a   Gadde, Kishore M ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; PLACEBO;

ADULT; ANORGASMIA; ARTICLE; BEHAVIOR THERAPY; BRIEF SOCIAL PHOBIA SCALE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH CENTER; NAUSEA; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; ROLE PLAYING; SELF REPORT; SOCIAL PHOBIA; STATISTICAL MODEL; TREATMENT OUTCOME; TREATMENT PLANNING;

ADULT; AMBULATORY CARE; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; LINEAR MODELS; MALE; PHOBIC DISORDERS; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; PYRIMIDINES; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; VIDEOTAPE RECORDING;

EID: 5044229135     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.61.10.1005     Document Type: Article

References (32)

1. Kessler RC, Stein MB, Berglund P. Social phobia subtypes in the National Comorbidity Survey. Am J Psychiatry. 1998;155:613-619.
2. Davidson JRT, Hughes DL, George LK, Blazer DG. The epidemiology of social phobia: findings from the Duke Epidemiological Catchment Area Study. Psychol Med. 1993;23:709-718.
3. Brown EJ, Heimberg RG, Juster H. Social phobia subtype and avoidant personality disorder: effect on severity of social phobia impairment and outcome of cognitive-behavioral treatment. Behav Ther. 1995;26:467-481.
4. Katzelnick DJ, Kobak KA, DeLeire T, Henk HJ, Greist JH, Davidson JRT, Schneier FR, Stein MB, Helstead CP. Impact of generalized social anxiety disorder in managed care. Am J Psychiatry. 2001;158:1999-2007.
5. Hidalgo RB, Barnett SD, Davidson JRT. Social anxiety disorder in review: two decades of progress. Int J Neuropsychopharmacol. 2001;4:279-298.
6. Heimberg RG, Liebowitz MR, Hope DA, Schneier FR, Holt CS, Welkowitz CA, Juster HR, Campeas R, Bruch MA, Cloitre M, Fallon B, Klein DF. Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. Arch Gen Psychiatry. 1998;55:1133-1141.
7. Turner SM, Beidel D, Jacobs RG. Social phobia: a comparison of behavior therapy and atenolol. J Consult Clin Psychol. 1994;62:350-358.
8. Clark DB, Agras WS. The assessment and treatment of performance anxiety in musicians. Am J Psychiatry. 1991;148:598-605.
9. Franklin ME, Jaycox LH, Foa EB. Social skills training. In: Hersen M, Bellack A, eds. Handbook of Comparative Treatments for Adult Disorders. 2nd ed. New York, NY: John Wiley and Sons; 1999:317-339.
10. Blomhoff S, Haug TT, Hellstrom K, Holme I, Humble M, Madsbutt P, Wold JE. Randomized controlled general practice trial of sertraline, exposure therapy and combined treatment in generalized social phobia. Br J Psychiatry. 2001;179:23-30.
11. Spitzer RL, First MB, Gibbon M, Williams JBW. Structured Clinical Interview for Axis I DSM-IVR Disorders: Patient Edition. New York: Biometrics Research Department, New York State Psychiatric Institute; 1996.
12. Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: Department of Health, Education, and Welfare; 1976:217-222. Publication (ADM) 76-338.
13. Heimberg RG, Dodge CS, Hope DA, Kennedy CR, Zollo L, Becker RE. Cognitive-behavioral group treatment of social phobia: comparison to a credible placebo control. Cognit Ther Res. 1990;14:1-23.
14. Davidson JRT, Miner CM, de Veaugh Geiss J, Tupler LA, Colket JT, Potts NLS. The Brief Social Phobia Scale: a psychometric evaluation. Psychol Med. 1997;27:161-166.
15. Turner SM, Beidel DC, Dancu CV, Stanley MA. An empirically derived inventory to measure social fears and anxiety: the Social Phobia and Anxiety Inventory. Psychol Assess. 1989;1:35-40.
16. Beidel DC, Turner SM, Cooley MR. Assessing reliable and clinically significant change in social phobia: validity of the Social Phobia and Anxiety Inventory. Behav Res Ther. 1993;31:331-337.
17. Barnett SD, Tharwani HM, Hertzberg MA, Sutherland SM, Connor KM, Davidson JRT. Tolerability of fluoxetine in posttraumatic stress disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:363-367.
18. Gibbons RD, Hedeker D, Elkin I, Waternaux C, Kraemer HC, Greenhouse JB, Shea MT, Imber SD, Sotsky SM, Watkins JT. Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Arch Gen Psychiatry. 1993;50:739-750.
19. Hedges L, Olkin I. Statistical Methods for Meta Analysis. New York, NY: Academic Press; 1985:88.
20. Haug TT, Hellstrom K, Blomhoff S, Humble M, Madsbutt P, Wold JE. The treatment of social phobia in general practice: is exposure therapy feasible? Fam Pract. 2000;17:114-118.
21. Gueorguieva R, Krystal JH. Move over AMOVA: progress in analyzing repeated-measures data and its reflection in articles published in the Archives of General Psychiatry. Arch Gen Psychiatry. 2004;61:310-317.
22. Connor KM, Rothbaum BO, Foa EB, Davidson JRT, Cahill SP, Cary CM. A controlled trial of combined sertraline and prolonged exposure therapy in posttraumatic stress disorder. Eur Neuropsychopharmacol. 2002;12(suppl 3):S35.
23. Huppert JD, Franklin ME, Foa EB, Davidson JRT. Study refusal and exclusion from a randomized treatment study of generalized social phobia. J Anxiety Disord. 2003;17:683-693.
24. Kobak KA, Greist JH, Jefferson JW, Katzelnick DJ. Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. J Clin Psychopharmacol. 2002;22:257-262.
25. Clark DM, Ehlers A, McManus F, Hackmann A, Fennell M, Campbell H, Flower T, Davenport C, Louis B. Cognitive therapy vs fluoxetine in generalized social phobia: a randomized placebo-controlled trial. J Consult Clin Psychol. 2003;71:1058-1067.
26. Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA. 1998;280:708-713.
27. Baldwin D, Bobes J, Stein DJ, Scharwachter I, Faure M. Paroxetine in social phobia/social anxiety disorder: randomized, double-blind, placebo-controlled study. Br J Psychiatry. 1999;175:120-126.
28. Allgulander C. Paroxetine in social anxiety disorder: a randomized placebo-controlled study. Acta Psychiatr Scand J. 1999;100:193-198.
29. Katzelnick DJ, Kobak KA, Greist JH, Jefferson JW, Mantle JM, Serlin RC. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry. 1995;152:1368-1371.
30. van Ameringen MA, Lane RM, Walker JR, Chokka PR, Goldner EM, Johnston DG, Lavalle YJ, Nandy S, Pecknold JC, Hadrava V, Swinson RP. Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry. 2001;158:275-281.
31. Moher D, Schulz KF, Attman D; CONSORT group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA. 2001;285:1987-1991.
32. Stangier U, Heidenreich T, Peitz M, Lauterbach W, Clark DM. Cognitive therapy for social phobia: individual versus group treatment. Behav Res Ther. 2003;41:991-1007.